XBiotech is committed to advancing its robust pipeline of potential breakthrough antibody therapies. Each of the Company’s targeted antibody candidates were discovered and developed using XBiotech’s proprietary True Human™ technology.
XBiotech is proud of its clinical research capabilities. All activities ranging from clinical study design, clinical site identification, initiation and medical monitoring to pharmacovigilance and U.S. FDA and European EMA submissions, are conducted entirely in-house by XBiotech’s clinical team. This is not only a highly cost-effective means of executing clinical programs, it creates the basis for powerful and dynamic product development capabilities.